Mateus Ramos Amorim

Dr. Mateus Ramos Amorim


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
OAO Aung
O Aung
MAMateus Ramos Amorim
Mateus Ramos Amorim
DMDavid Mendelowitz
David Mendelowitz
VPVsevolod Y. Polotsky
Vsevolod Y. Polotsky
Serotonin or 5-hydroxytryptamine (5-HT) is a ubiquitous neuro-modulator–transmitter that acts in the central nervous system, playing a major role in the control of breathing and other physiological functions. The midbrain, pons, and medulla regions contain several serotonergic nuclei with distinct physiological roles, including regulating the hypercapnic ventilatory response, upper airway patency, and sleep–wake states. Obesity is a major risk factor in the development of sleep-disordered breathing (SDB), such as obstructive sleep apnea (OSA), recurrent closure of the upper airway during sleep, and obesity hypoventilation syndrome (OHS), a condition characterized by daytime hypercapnia and hypoventilation during sleep. Approximately 936 million adults have OSA, and 32 million have OHS worldwide. 5-HT acts on 5-HT receptor subtypes that modulate neural control of breathing and upper airway patency. This article reviews the role of 5-HT in SDB and the current advances in 5-HT-targeted treatments for SDB.

15 April 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MAMateus Ramos Amorim
Mateus Ramos Amorim
NWNoah R. Williams
Noah R. Williams
OAO. Aung
O. Aung
MRMelanie Alexis Ruiz
Melanie Alexis Ruiz
FAFrederick Anokye-Danso
Frederick Anokye-Danso
VPVsevolod Y. Polotsky
Vsevolod Y. Polotsky
Weight loss medications are emerging candidates for pharmacotherapy of sleep-disordered breathing (SDB). A melanocortin 4 receptor (MC4R) agonist, setmelanotide (Set), is used to treat obesity caused by abnormal melanocortin and leptin signaling. We hypothesized that Set can treat SDB in mice with diet-induced obesity. We performed a proof-of-concept randomized crossover trial of a single dose of Set versus vehicle and a 2-week daily Set versus vehicle trial, examined colocalization of Mc4r mRNAs with the markers of CO 2 -sensing neurons Phox2b and neuromedin B in the brainstem, and expressed Cre -dependent designer receptors exclusively activated by designer drugs (DREADDs) or caspase in obese Mc4r-Cre mice. Set increased minute ventilation across sleep/wake states, enhanced the hypercapnic ventilatory response (HCVR), and abolished apneas during sleep. Phox2b + neurons in the nucleus of the solitary tract (NTS) and the parafacial region expressed Mc4r . Chemogenetic stimulation of the MC4R + neurons in the parafacial region, but not in the NTS, augmented HCVR without any changes in metabolism. Caspase elimination of the parafacial MC4R + neurons abolished effects of Set on HCVR. Parafacial MC4R + neurons projected to the respiratory premotor neurons retrogradely labeled from C3–C4. In conclusion, MC4R agonists enhance the HCVR and treat SDB by acting on the parafacial MC4R + neurons.